EUCTR2005-003732-22-GB进行中（未招募）1 期
Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality) - Azacitidine for MDS with high risk cytogenetics
Kings College London0 个研究点目标入组 43 人开始时间: 2005年9月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Chromosome 7 or complex cytogenetic abnormality in MDS/AML
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Allergy to drug
研究者
相似试验
进行中（未招募）
不适用
A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed treatment with corticosteroidsChronic Graft versus Host DiseaseMedDRA version: 18.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-005659-19-GBniversity of Birmingham
进行中（未招募）
不适用
?Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs)? - MDS0706EUCTR2007-003943-55-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
进行中（未招募）
1 期
Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availabilityEUCTR2010-018467-42-DEniversity Medical Center Hamburg-Eppendorf110
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-DKMDSG30
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-SEMDSG30